Literature DB >> 11096726

Paraneoplastic Diseases of the Nervous System.

.   

Abstract

Several neurologic paraneoplastic disorders are believed to be caused by an autoimmune reaction against an antigen or antigens coexpressed by tumor cells and neurons. Of the paraneoplastic syndromes, the Lambert-Eaton myasthenic syndrome (LEMS)--in which autoantibodies downregulate voltage-gated calcium channels at the presynaptic nerve terminal--is associated with the strongest evidence of an autoimmune cause. For the other syndromes, including cerebellar degeneration, multifocal encephalomyelitis, sensory neuronopathy, limbic encephalitis, opsoclonus-myoclonus, and retinal degeneration, an autoimmune cause is indicated by the presence of specific anti-neuronal antibodies. These antibodies serve as a useful diagnostic tool, but their actual role in causing neuronal injury and clinical disease remains unclear. A small percentage of patients with paraneoplastic disorders shows major neurologic improvement after successful treatment of the associated tumor. Of patients who require further therapy for the neurologic disorder, those with LEMS have the best outcome. The response to immunosuppression among patients with paraneoplastic central nervous system (CNS) dysfunction is much less favorable. Although exceptions clearly exist, most patients with CNS paraneoplastic disorders do not improve despite tumor treatment and immunosuppressive therapy. It is likely that many patients already have irreversible neuronal injury at the time of diagnosis. The decision to attempt immunosuppressive treatment must be made on an individual basis.

Entities:  

Year:  1999        PMID: 11096726     DOI: 10.1007/s11940-996-0005-y

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  35 in total

1.  Early diagnosis and intravenous immune globulin therapy in paraneoplastic cerebellar degeneration.

Authors:  J W Moll; S C Henzen-Logmans; F G Van der Meché; C H Vecht
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-01       Impact factor: 10.154

2.  Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome.

Authors:  J Newsom-Davis; N M Murray
Journal:  Neurology       Date:  1984-04       Impact factor: 9.910

3.  Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer.

Authors:  F A Luque; H M Furneaux; R Ferziger; M K Rosenblum; S H Wray; S C Schold; M J Glantz; K A Jaeckle; H Biran; M Lesser
Journal:  Ann Neurol       Date:  1991-03       Impact factor: 10.422

4.  Therapy for paraneoplastic neurologic syndromes in six patients with protein A column immunoadsorption.

Authors:  L M Cher; F H Hochberg; J Teruya; M Nitschke; R F Valenzuela; J D Schmahmann; M Herbert; H D Rosas; C Stowell
Journal:  Cancer       Date:  1995-04-01       Impact factor: 6.860

5.  Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome.

Authors:  H Lundh; O Nilsson; I Rosén; S Johansson
Journal:  Acta Neurol Scand       Date:  1993-08       Impact factor: 3.209

6.  Azathioprine toxicity in neuromuscular disease.

Authors:  J T Kissel; R J Levy; J R Mendell; R C Griggs
Journal:  Neurology       Date:  1986-01       Impact factor: 9.910

7.  Limbic encephalitis and immunological perturbations in two patients with thymoma.

Authors:  J C Antoine; J Honnorat; C T Anterion; M Aguera; L Absi; P Fournel; D Michel
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-06       Impact factor: 10.154

8.  Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients.

Authors:  R W Tim; J M Massey; D B Sanders
Journal:  Ann N Y Acad Sci       Date:  1998-05-13       Impact factor: 5.691

9.  3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS).

Authors:  D B Sanders
Journal:  Ann N Y Acad Sci       Date:  1998-05-13       Impact factor: 5.691

10.  Long-term outcome in children with opsoclonus-myoclonus and ataxia and coincident neuroblastoma.

Authors:  P S Koh; J G Raffensperger; S Berry; M B Larsen; H S Johnstone; P Chou; S R Luck; M Hammer; S L Cohn
Journal:  J Pediatr       Date:  1994-11       Impact factor: 4.406

View more
  2 in total

Review 1.  Central nervous system toxicity from cancer treatment.

Authors:  Terri Armstrong; Mark R Gilbert
Journal:  Curr Oncol Rep       Date:  2004-01       Impact factor: 5.075

Review 2.  Rapidly progressive dementia.

Authors:  Michael D Geschwind; Aissa Haman; Bruce L Miller
Journal:  Neurol Clin       Date:  2007-08       Impact factor: 3.806

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.